After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B

t’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline.

A few weeks back, Pfizer out-licensed two of its antibody-drug conjugate (ADC) candidates, to be known as PYX-201 and PYX-203, to the biotech, while also giving Pyxis a license for its ADC technology platform, including various payload classes, linker technology and site-specific conjugation techniques for the future development of additional ADCs.